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aAbstract
Background: CT-based attenuation correction (CT-AC) using contrast-enhancement
CT impacts 111In-SPECT image quality and quantification. In this study we assessed
and evaluated the effect.
Methods: A phantom (5.15 L) was filled with an aqueous solution of In-111. Three
SPECT/CT scans were performed: (A) no IV contrast, (B) with 100-mL IV contrast,
and (C) with 200-mL IV contrast added. Scan protocol included a localization CT, a
low-dose CT (LD), and a full-dose CT (FD). Phantom, LD and FD scan series were
performed at 90, 120, and 140 kVp. Phantom data were evaluated looking at mean
counts in a central volume.
Ten patients referred for 111In-octreotide scintigraphy were scanned according to
our clinical 111In-SPECT/CT protocol including a topogram, a LD (140 kVp), and a FD
(120 kVp). The FD/contrast-enhanced CT was acquired in both arterial (FDAP) and
venous phase (FDVP) following a mono-phasic IV injection of 125-mL Optiray
(4.5 mL/s). For patient data, we report image quality, Krenning scores, and mean/
max values for liver and tumor regions.
Results: Phantoms: in uncorrected emission data, mean counts (average ± SD)
decreased with increasing IV concentration: (A) 119 ± 9, (B) 113 ± 8, and (C) 110 ± 9.
For all attenuation correction (AC) scans, the mean values increased with increasing
iodine concentration.
Patients: there were no visible artifacts in single photon emission computed
tomography (SPECT) following CT-AC with contrast-enhanced CT. The average
score of image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for LD, arterial phase,
and venous phase, respectively.
A total of 16 lesions were detected. The Krenning scores of 13/16 lesions were
identical across all scan series. The max pixel values for the 16 lesions showed
generally lower values for LD than for contrast-enhanced CT.
Conclusions: In 111In-SPECT/CT imaging of phantoms and patients, the use of IV
CT contrast did neither degrade the SPECT image quality nor affect the clinical
Krenning score. Reconstructed counts in healthy liver tissues were unaffected, and
there was a generally lower count value in lesions following CT-AC based on the
LD non-enhanced images. Overall, for clinical interpretation, no separate low-dose
CT is required for CT-AC in 111In-SPECT/CT.
Keywords: Combined SPECT/CT; Attenuation correction; CT contrast agents2015 Klausen et al.; licensee Springer. This is an open access article distributed under the terms of the Creative Commons
ttribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
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Diagnostic imaging is essential in the workup of patients with a variety of diseases. Nu-
clear medicine imaging techniques, such as single photon emission computed tomog-
raphy (SPECT) and positron emission tomography (PET), have for decades made an
impact on the diagnostic pathways for a variety of indications in oncology, neurology,
and cardiology [1-6]. Compared to PET, SPECT has the advantage of using radioactive
labeled tracer molecules with relatively long physical half-lives that to a great extent are
similar to the biological processes under observation. In general, isotopes for SPECT
imaging are more easily attainable, and SPECT is generally more widely available than
PET. Furthermore, SPECT has the ability, based on photon energy information, to per-
form dual isotope scans in a simple way. With recent advances in calibration, data pro-
cessing, and, perhaps most importantly, the combination of SPECT and computed
tomography (CT), SPECT has now become a quantitative, nuclear medicine imaging
technique [7].
A major application of SPECT is in myocardial perfusion imaging [8,9]. This applica-
tion and the wish to expand on its use have led to the promotion of separate transmis-
sion imaging as a pre-requisite to derive SPECT attenuation correction factors [10].
The increased wish for fast, noise free, and clinically viable SPECT attenuation correc-
tion (AC) was a primary drive for the development of combined SPECT/CT technology
[11]. Therefore, the reasoning for the combination of SPECT and CT was distinctly dif-
ferent from that for the combination of PET and CT [12], which was developed to ad-
dress a clinical need of fusing PET and CT images routinely and allowing for extended
anatomical coverage adding only little additional scan time [13].
LaCroix and colleagues first presented concepts for CT-based attenuation correction
(CT-AC) of SPECT data [14] long before the first presentation of a clinical SPECT/CT
system [15]. Based on simulations with a mono-energetic X-ray beam, the authors
showed that SPECT quantification of the myocardium was accurate to within 9% of the
true activity concentration. Blankespoor and colleagues took on these studies and
adopted CT transmission imaging and CT-based corrections for attenuation and scatter
of SPECT in a prototype SPECT/CT system [16]. Further studies with their prototype
SPECT/CT system and subsequent assessments of SPECT quantification in the heart
and torso [17] have contributed to a great extent to the development of the first
SPECT/CT system presented by GE Healthcare in 2000 [18]. Today, four major com-
mercial vendors provide many different designs of SPECT/CT systems for clinical use,
all of which provide CT-AC image reconstruction routinely.
With the dissemination of SPECT/CT, the range of applications has expanded from
myocardial perfusion imaging to oncology indications, such as torso imaging in patients
with neuroendocrine tumors (NETs), differentiated thyroid carcinomas, lymphoma, and
sentinel node lymphoscintigraphy [2]. SPECT/CT imaging has also been shown to posi-
tively affect the localization of scintigraphic lesions, to aid in the differentiation of be-
nign and malignant sites, and to guide biopsies, to name a few applications [19,20].
Several of these indications require the administration of CT contrast agents for en-
hancement of the vascular system and better differentiation of parenchymal tissue up-
take. The use of CT contrast in combined imaging has been the subject of debate
among PET/CT users [21,22], the reason being that standard, segmentation, and bi-
linear scaling methods of CT-AC [23,24] fail to adequately scale contrast-enhanced
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sues can be addressed by using modified imaging protocols [25].
Nonetheless, similar concerns among SPECT/CT users have limited the wider adop-
tion of contrast-enhanced CT protocols as part of clinical SPECT/CT imaging. If CT
contrast is indicated and used then most SPECT/CT imaging protocols entail a non-
enhanced, low-dose CT for the purpose of attenuation correction and a contrast-
enhanced CT for the purpose of advanced image fusion. Prior studies on the effect of
CT contrast in SPECT/CT are sparse. Römer et al. reported [26] IV and positive oral
contrast to have only a minor influence on calculated attenuation coefficients. Another
study, using phantom data and IV contrast concentrations several times higher than
those observed in clinical practice, has demonstrated a 36% overestimation of the AC-
SPECT activity unit [27].
In this study, we assess the effect of IV contrast enhancement on 111In-SPECT image
quality and quantification following CT-based attenuation correction using phantoms
with clinically relevant iodine contrast concentration and in oncology patients.Methods
Phantom study
A 20-cm cylinder phantom (5.15 L) was filled with water (Figure 1), and three separate
imaging conditions were prepared for using IV contrast (Optiray, 350 mg/mL iodine,
Mallinckrodt Pharmaceuticals, Hennef, Germany):
(PC0) No IV contrast added
(PC100) 100-mL IV contrast (equals 6.8 g iodine/L)
(PC200) 200-mL IV contrast (equals 13.6 g iodine/L)
For each of the three phantom conditions (PC0, PC100, PC200), 50 MBq In-111 was
added to the water solution in the cylinder (10 kBq/mL). Based on our clinical protocol,
50 MBq was chosen as a reasonable number with an injection of 200 MBq 48 h before
scan. The active phantom was centered in the field-of-view of a clinical SPECT/CT sys-
tem (Philips Precedence 16 slice CT, two-headed gamma camera, Philips Medical Sys-
tems, Eindhoven, the Netherlands) for imaging. For each of the phantom conditions,
the SPECT/CT protocol included a localization scan, spiral CT, and a single-bed
SPECT acquisition (128 projections, 20 s/position, matrix size 128 × 128, scan time
22 min) using two energy windows centered at 171 and 245 keV with a width of 20%
and a medium energy general purpose (MEGP) collimator. In each protocol, the spiral
CT was acquired as:
 a low-dose CT (LD): 38 mA, 5-mm slice thickness, pitch 0.94, rotation time 0.5 s
and
 a full-dose CT (FD): 469 mA, 2-mm slice thickness, pitch 0.94, rotation time 0.5 s
In both LD and FD scan series, the CT scans were performed at 90, 120, and 140
kVp yielding for each phantom preparation that were used a total of six different data-
sets as input to AC-SPECT image reconstruction. The μ-maps for AC were derived for
Figure 1 A 20-cm cylinder phantom (5.15 L).
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standard vendor software. In addition, the SPECT images of all three phantom condi-
tions were reconstructed without AC (noAC). In total, the three phantom sets each
comprise one noAC-SPECT and six AC-SPECT images. All SPECT data were recon-
structed iteratively using the Philips Astonish algorithm including the built-in scatter
correction but without additional filtering: 4 iter/16 sub, pixel size 4.66 mm ×
4.66 mm. Figure 2 summarizes the reconstruction pathways and reconstructed image
data.Patient study
Ten patients (seven males, three females) referred for 111In-octreotide scintigraphy
were consecutively enrolled in the study (from August 2012). All patients had con-
firmed SPECT-positive lesions.
The mean age was 63.4 years (range 53 to 76 years) and the mean weight was 75 ±
19 kg with an average BMI of 23.7 ± 2.5. Patients were injected with 220 ± 16 MBq
111In-pentetreotide (Octreoscan™) from Mallinckrodt Pharmaceuticals, Hennef,
Germany, and scanned 48 h post-injection. All patients were positioned in the head-
first supine position with arms up. The relevant areas for the combined SPECT/CT
examination were defined based on a prior whole-body planar scintigraphy. The axial
field-of-view typically covered the abdomen or the thorax, depending on the findings
from the scintigraphy scan.
Phantom scan and reconstructions 
Topogram
Low dose CT (LD) 
SPECT
No AC 
Full dose CT (FD) 








90 kVp 140 kVp 120 kVp 
Figure 2 Overview of scan flow and reconstructions. A total of seven SPECT data sets were reconstructed
for each scan series; one noAC and three AC based on LD with different kVp and three AC based on FD with
different kVp.
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cluding a topogram, a LD (140 kVp, 38 mA, 5-mm slice thickness, pitch 0.94, rotation
time 0.5 s), a FD (120 kVp, 469 mA, 2-mm slice thickness, pitch 0.94, rotation time
0.5 s), and a single-bed SPECT scan (using two energy windows centered at 171 and
245 keV with a width of 20% ,MEGP collimator, 128 projections, 20 s/position, matrix
size 128 × 128, scan time 22 min). The FD contrast-enhanced CT was acquired in
both the arterial and venous phase following a mono-phasic IV injection of 125 mL
Optiray (4.5 mL/s). The time delay between arterial phase and venous phase was 70 s.
CT images were reconstructed into 512 by 512 matrices.
SPECT images were reconstructed without (noAC) and with AC. Iterative SPECT
image reconstruction was performed using the implemented Astonish algorithm with
scatter correction and without additional filtering: 4 iter/16 sub, pixel size 4.66 mm ×
4.66 mm. AC-SPECT data were reconstructed with the three CT series: LD, FD in the
arterial phase (FDAP), and FD in the venous phase (FDVP).
During the initial reconstruction steps, an experienced nuclear medicine phys-
ician visually inspected the CT and noAC-SPECT images for misalignment. If a
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ally to match the noAC-SPECT and CT-AC was performed followed by image
recon (Table 1).Data evaluation
Phantoms
For all scan series, we report the average volume of interest (VOI) value (reconstructed
counts) calculated from central circles with a radius of 5 cm placed on 11 central image
planes of the phantom.
Patients
An experienced nuclear medicine physician with over 10 years of clinical SPECT ex-
perience performed clinical evaluation of all AC-SPECT images. All reconstructions
were evaluated blinded and presented in random order. On this data the following were
performed:
 SPECT images were screened for image artifacts (yes/no) and assessed for overall
image quality using a scale of 5 (grade 1 = very poor, 2 = poor, 3 = acceptable,
4 = good, 5 = very good).
 SPECT-positive lesions were detected and values (reconstructed counts) for the
hottest lesion in each organ were reported.
 The lesions were scored visually using the 4-point Krenning score scale [28]; lower
than (grade 1), equal to (grade 2), or greater than (grade 3) normal liver tissue; or
higher than normal spleen or kidney uptake (grade 4).
Fourth, lesion max values were reported, and fifth, we report the average value of a
10-cm2 circular region of interest (ROI) placed on healthy liver tissue in a region with
no or little IV contrast uptake.Table 1 Visually based misalignment (values in mm) between LD, FDAP, and FDVP and
their corresponding SPECT data
Patient # LD_MC FDAP_MC FDVP_MC
x y z Rotation x y z Rotation x y z Rotation
1 0 0 −10 0 0 0 −12 0 0 0 −28 0
2 0 0 0 0 0 0 0 0 0 0 −18 0
3 0 0 0 0 0 −15 −31 0 0 −10 −30 0
4 0 0 0 0 0 −5 −20 0 0 −5 −30 0
5 0 0 0 0 0 −10 −30 0 0 −10 −30 0
6 0 0 0 0 0 −10 −20 0 0 −10 −20 0
7 0 0 0 0 0 −10 −25 0 0 −10 −25 0
8 0 0 0 0 0 0 0 0 0 0 −15 0
9 0 0 0 0 0 −5 0 0 0 −5 0 0
10 0 0 0 0 0 0 0 0 0 0 0 0
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A paired t-test (two-tailed) was used for comparison of reconstructed counts in the le-
sions and the liver between the LD, FDAP, and FDVP reconstructions. The significance
level was set to p < 0.05.Results
Phantom studies
With uncorrected emission data (noAC), mean counts decreased with increasing iodine
concentration (Figure 3). For all AC scans, the mean reconstructed count value in-
creased as a function of increasing iodine concentration. The slope of this function de-
creased with increasing kVp, and the slope values were higher for LD than for FD
(Figure 4, Table 2). Furthermore, for all AC scans, the mean counts for LD were about
5% higher than for the corresponding FD.Patient studies
There were no visible artifacts in the SPECT images following CT-AC with the LD,
FDAP, or the FDVP (Figure 5).
The average score of SPECT image quality was 4.1 ± 0.3, 3.8 ± 0.4, and 4.2 ± 0.4 for
LD, FDAP, and FDVP, respectively. The t-test showed a significant difference (p < 0.04)
between FDAP and FDVP only (Table 3). In total, 16 SPECT-positive lesions were eval-
uated with max pixel value of 293 ± 214, 312 ± 226, and 307 ± 218 for LD, FDAP, and
FDVP, respectively (Table 3).
For 13 out of 16 lesions, the Krenning score was identical in all the CT phases. In the
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Figure 3 noAC In-111 reconstructed counts for each of the three phantom conditions. noAC In-111
reconstructed counts for each of the three phantom conditions PC0, PC100, and PC200 corresponding to 0,
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Figure 4 SPECT mean reconstructed count value as a function of increasing iodine concentration.
All data are AC using LD at 90, 120, and 140 kVp or FD at 90, 120, and 140 kVp.
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for LD than for FD; p < 0.003 and p < 0.05 for arterial and venous phase, respectively.
On average, LD values were 5.8% ± 7% and 6.1% ± 8% lower.
Across all 10 patients, there were no significant differences in the mean count value
for the liver ROI (Table 4). However, in individual patients, there were differences up to
around 8%. The highest difference between the three scans series was between the two
FD series with FDVP (venous phase) on average being 2.1% ± 3% higher than FDAP (ar-
terial phase).Discussion
Our study demonstrates that a CT scan with an iodine-based IV contrast agent can be
used for CT-based attenuation correction of a 111In-SPECT scan in combined modality
with SPECT/CT scanning. No artifacts were seen in the SPECT images, and the clinical
interpretation using Krenning score did not change significantly. However, changes in
quantitative values in the range of 6% were observed. So for clinical interpretation with-
out high-quantitative accuracy, no separate low-dose CT is required for CT-AC in
111In-SPECT/CT.
Administration of iodine-based contrast increases the attenuation by increasing the
photoelectric absorption of photons in the energy interval of interest in CT and in
SPECT, and this effect is evident in the uncorrected SPECT data (Figure 3). However,
due to the low-mean energy of the Bremsstrahlung spectrum from the CT compared to
most radioisotopes used in SPECT, and the rapid decline of photoabsorption with en-
ergy, the attenuation enhancement is higher in the CT acquisition than in the SPECT
acquisition. When CT is used for attenuation correction, a conversion of Hounsfield
Unit (HU) into attenuation values at the proper SPECT energy is performed [14]. This
conversion assumes a certain tissue composition (dependent on the HU) and does not
account for the presence of iodine. The result will be an overestimation in the attenu-
ation values used for the correction of the emission data and, thus, results in a higher
Table 2 The slope of the mean values (reconstructed counts) as a function of increasing
iodine concentration




The slope decreased with increasing kVp, and the values were higher for LD than for FD.
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ergy, as seen by the decreasing slope with increasing CT energy (Table 2), is consistent
with this.
The shift in average attenuation values may propagate through CT-AC and cause
local artifacts that may be incorrectly interpreted in the clinical reading. This was dis-
cussed by Roemer et al. [26] when presenting findings where the presence of CT con-
trast had a clinically relevant effect on SPECT quantification.
Their findings are in line with this study that indicate generally lower count values
(6%) in 111In-SPECT-positive lesions following CT-AC using LD compared to contrast
enhanced CT (Table 3).
To obtain quantitative images in PET and SPECT, many corrections such as attenu-
ation, scatter, and partial volume correction need to be taken into account during
image reconstruction. The AC challenges for SPECT are larger by far compared to
PET, in essence, due to the fundamental physical differences in decay scheme for PET
and SPECT isotopes and the subsequent differences in scanner design [30]. However,
by applying attenuation, scatter, and partial volume correction, activity estimations can
be obtained with error levels of 3% to 5% for Tc-99m, In-111, I-123, and I-131, as
shown by Shcherbinin et al. [29] in phantom studies. In clinical settings, SPECT with
Tc-99m can be quantitative with errors less than 5% to 10% [30-32]. With errors on the
order of just 10%, quantitative SPECT can be promoted further in a clinical setting [7].
On the scanner side, vendors are also starting to move towards quantitative SPECT/CT




Figure 5 CT images. Top row: CT images for LD, FDAP, and FDVP. Middle row: AC-SPECT images for LD,
FDAP, and FDVP. Lower row: first image noAC-SPECT images; second images percent difference between
LD- and FDAP-SPECT; third image percent difference between LD-FDVP-SPECT.
Table 3 Image score quality for the 10 patients showed significant difference (p < 0.04)
between FDAP and FDVP only
Patient # Image score Lesion value (max pixel) Krenning score Lesion location
LD FDAP FDVP LD FDAP FDVP LD, FDAP, FDVP
1 4 4 5 498 516 446 4, 4, 4 Liver
135 145 146 3, 3, 3 Lymph Node
2 4 3 4 678 671 661 4, 4, 4 Liver
3 4 3 4 49 46 55 3, 3, 3 Liver
158 171 174 3, 3, 3 Lymph Node
4 4 4 4 753 813 790 4, 4, 4 Lymph Node
5 4 4 4 270 320 309 3, 3, 3 Pancreas
6 5 4 4 142 162 168 3, 3, 3 Lymph Node
7 4 4 5 65 67 68 3, 3, 3 Liver
543 593 593 4, 4, 4 Lymph Node
8 4 4 4 249 295 290 3, 4, 4 Liver
186 186 192 3, 3, 4 Bone
9 4 4 4 131 133 130 3, 3, 3 Liver
358 385 385 3, 4, 4 Lymph Node
10 4 4 4 382 410 423 4, 4, 4 Liver
89 83 81 3, 3, 3 Lymph Node
Average 4.1 ± 0.3 3.8 ± 0.4 4.2 ± 0.4 293 ± 214 312 ± 226 307 ± 218 4.1, 3.8, 4.2 N/A
Max pixel values for the 16 lesions shows significantly lower values for LD than for FD; p < 0.003 and p < 0.05 for arterial
and venous phase, respectively. On the average, LD values are 6% ± 7% and 6% ± 8% lower. For 13 out of 16 lesions, the
Krenning score is identical in all the CT phases. In the remaining three lesions (highlighted), the Krenning score differed
by no more than one.
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fects the SPECT quantification; nevertheless, the effect is small and similar to the one
seen in PET. Therefore, it is likely that the continuing development/use of quantitative
SPECT in the clinic can include IV-contrast-enhanced CT and still maintain the overall
goal to provide reliable and accurate images.
This is relevant because, as shown by Wieder et al. [34], SPECT/CT is not used to its
full potential, mainly because SPECT/CT is operated in nuclear medicine departments
only, but also because contrast is rarely ever used; this study shows that the additional
LD can be spared and IV contrast can be used. This will help reduce patient exposure
and scan time, and using IV contrast in combined modality with SPECT/CT will be
more cost effective since the patient will be spared a standalone CT scan. Furthermore,
as it is the case for PET/CT, a SPECT/CT scan with a diagnostic quality CT including
IV (and oral) contrast agents is advantageous compared with a CT scan performed with
IV contrast on one occasion plus a SPECT/CT with LD for image fusion and attenu-
ation correction performed on another occasion. To our knowledge, the latest guide-
lines from the European Association of Nuclear Medicine (EANM) or the Society of
Nuclear Medicine and Molecular Imaging (SNMMI) dates back to 2006 [35] and
should be adhered to regarding the potential increasing use of CT in combination with
SPECT.
The number of patients included in this study was small, and the anatomical distribu-
tion of lesions shows little variation (14 out of 16 lesions were located in the liver or
lymph nodes, Table 3). A bias due to patient selection is a possibility, but there is no
Table 4 Reconstructed counts from liver ROI
Reconstructed counts from liver ROI
Patient # LD FDAP FDVP
1 78.4 80.3 80.3
2 84.2 84.7 90.2
3 22.4 21.0 22.6
4 56.1 54.0 54.9
5 49.3 48.8 49.8
6 45.5 44.2 44.8
7 26.3 25.1 25.3
8 22.7 22.3 22.9
9 44.6 47.2 47.1
10 33.6 33.0 32.3
t-test (p-values) 0.58 0.34 0.11
Mean reconstructed count values from a 10 cm2 ROI (circle) placed on healthy liver tissue in a region with little IV
contrast uptake.
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to the presence of IV contrast. However, one could consider demonstrating the effect
of IV contrast in a larger patient group with a different pathology.
Differences in breathing status in a combined modality scanner are among the most
prominent problems for the use of CT data in attenuation correction. The misalign-
ment adds bias to SPECT images [36], and therefore, at clinical evaluation of
attenuation-corrected scans, special attention should be given to possible misalign-
ments between SPECT and CT. If there is a misalignment, ideally, a manual realign-
ment of CT and SPECT images should be performed followed by a new reconstruction.
In the present study, misalignments between SPECT and CT were seen in 9 out of 10
patients.Conclusions
In 111In-SPECT/CT imaging of phantoms and patients, the use of IV CT contrast did
neither degrade the SPECT image quality nor affect the clinical Krenning score. Recon-
structed counts in healthy liver tissues were unaffected, and there was a generally lower
count value in lesions following CT-AC based on the LD non-enhanced images. Over-
all, for clinical interpretation, no separate low-dose CT is required for CT-AC in
111In-SPECT/CT.
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